Takara Bio Inc.   Report issue

For profit Phase 1 Phase 2
Founded: Kusatsu Japan (1925)
Status: No NME R&D (1925)

Organization Overview

First Clinical Trial
2009
NCT01017185
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Takara Bio Inc. | TAKARA BIOTECHNOLOGY(DALIAN)CO.,LTD.

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Breast Neoplasms (Phase 1)

Carcinoma (Phase 1)

Head and Neck Neoplasms (Phase 1)

Leukemia (Phase 2)

Leukemia, Lymphoid (Phase 2)

Lymphoma (Phase 2)

Lymphoma, B-Cell (Phase 2)

Lymphoma, Non-Hodgkin (Phase 2)

Melanoma (Phase 2)

Neoplasms (Phase 1)

Pancreatic Neoplasms (Phase 1)

Parkinson Disease (Phase 2)

Precursor Cell Lymphoblastic Leukemia-Lymphoma (Phase 2)

Sarcoma (Phase 2)

Sarcoma, Synovial (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 14
  • # of Trial APIs: 21